2. Nuvation Bio Inc. (NYSE:NUVB)
Number of Hedge Fund Holders: 42
Market Capitalization: $1.60 billion
Share Price: $4.55
Nuvation Bio Inc. (NYSE: NUVB) combines an approved oncology product with a developing pipeline, giving investors both commercial results and clinical milestones to assess. Its shares had fallen more than 45% in 2026, according to the supplied figures, despite improving product revenue.
IBTROZI, or taletrectinib, is the near-term commercial driver. The FDA-approved treatment targets locally advanced or metastatic ROS1-positive non-small cell lung cancer, a genetically defined subset of the broader lung cancer market.
Second-quarter net product revenue reached $23.2 million, increasing 25% from the preceding quarter. The company also reported that approximately 85% of new patient starts were in patients who had not previously received a tyrosine kinase inhibitor, an important segment for its commercial strategy.
Regulatory progress added further support. In September, the FDA approved updated labeling incorporating longer-duration response data from the TRUST-I study, without new safety signals identified through the additional follow-up.
Beyond the approved product, safusidenib provides a second major development opportunity. The investigational IDH1 inhibitor is being studied in IDH1-mutant glioma, expanding the company’s exposure across precision oncology.
Analysts have remained constructive. Citi initiated coverage on September 30 with a Buy rating and a $12 price target. Cantor Fitzgerald reiterated an Overweight rating and a $12 target on August 21, with a forecast that IBTROZI sales could eventually peak at $965 million.
That sales estimate remains an analyst projection. Continued prescribing growth, treatment duration, competition, and successful pipeline development will determine how much of the opportunity becomes revenue.
Ranking rationale: Nuvation Bio Inc. (NYSE: NUVB) ranks second with 42 hedge-fund holders. Its approved lung cancer treatment, sequential product-sales growth, and additional oncology programs support its position, while the share-price decline highlights the gap between business progress and market expectations.
